Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at industrialstockmovers.com, will continue to monitor these healthtech companies to see if the momentum continues. IndustrialStockMovers.com is also looking into these tickers IEA, LICY, SOL, HDSN, RCMT and more..
Arrowhead Pharmaceuticals, ARWRRecent ARWR Stock Price: $47.02
Summary: Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.
Patrick Trucchio analyst at H.C. Wainwright reiterates coverage on Arrowhead Pharmaceuticals (ARWR) stock in the energy sector with a Buy rating and has set ARWR's stock price target at $ 110.
TipRanks.com reports that Arrowhead Pharmaceuticals currently has n/a analysts offering 12-month price targets on ARWR and the consensus is a Strong Buy rating with an average stock price target of n/a. The most recent ARWR stock price we have is $47.02 and we are not making any ARWR forecasts at this time.
In addition, TradingView issued a Buy rating for ARWR over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ARWR. industrialstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ARWR, please click here >>
Iovance Biotherapeutics, IOVA
Recent IOVA Stock Price: $12.31
Summary: Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.
Reni Benjamin analyst at JMP Securities reiterates coverage on Iovance Biotherapeutics (IOVA) stock in the energy sector with a Buy rating and has set IOVA's stock price target at $ 25.
TipRanks.com reports that Iovance Biotherapeutics currently has 10 analysts offering 12-month price targets on IOVA and the consensus is a Strong Buy rating with an average stock price target of $24.40. The most recent IOVA stock price we have is $12.31 and we are not making any IOVA forecasts at this time.
In addition, TradingView issued a Neutral rating for IOVA over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on IOVA. industrialstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on IOVA, please click here >>
Eli Lilly & Co, LLY
Recent LLY Stock Price: $302.50
Summary: Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Robyn Karnauskas analyst at Truist Financial reiterates coverage on Eli Lilly & Co (LLY) stock in the energy sector with a Buy rating and has set LLY's stock price target at $ 348.
TipRanks.com reports that Eli Lilly & Co currently has 11 analysts offering 12-month price targets on LLY and the consensus is a Strong Buy rating with an average stock price target of $350.10. The most recent LLY stock price we have is $302.50 and we are not making any LLY forecasts at this time.
In addition, TradingView issued a n/a rating for LLY over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on LLY. industrialstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on LLY, please click here >>
Arvinas Holding Company, ARVN
Recent ARVN Stock Price: $55.83
Summary: Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.
Terence Flynn analyst at Morgan Stanley reiterates coverage on Arvinas Holding Company (ARVN) stock in the energy sector with a Hold rating and has set ARVN's stock price target at $ 63.
TipRanks.com reports that Arvinas Holding Company currently has n/a analysts offering 12-month price targets on ARVN and the consensus is a Strong Buy rating with an average stock price target of n/a. The most recent ARVN stock price we have is $55.83 and we are not making any ARVN forecasts at this time.
In addition, TradingView issued a Buy rating for ARVN over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ARVN. industrialstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ARVN, please click here >>
Alignment Healthcare, ALHC
Recent ALHC Stock Price: $16.75
Summary: Alignment Healthcare Inc. is a consumer-centric platform delivering customized health care in the United States to seniors and those who need it most, the chronically ill and frail, through its Medicare Advantage plans. Alignment Healthcare Inc. is based in ORANGE, Calif.
John Ransom analyst at Raymond James reiterates coverage on Alignment Healthcare (ALHC) stock in the energy sector with a Buy rating and has set ALHC's stock price target at $ 22.
TipRanks.com reports that Alignment Healthcare currently has n/a analysts offering 12-month price targets on ALHC and the consensus is a Strong Buy rating with an average stock price target of n/a. The most recent ALHC stock price we have is $16.75 and we are not making any ALHC forecasts at this time.
In addition, TradingView issued a Buy rating for ALHC over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ALHC. industrialstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ALHC, please click here >>
Twist Bioscience, TWST
Recent TWST Stock Price: $56.56
Summary: Twist Bioscience Corporation operates as a biotechnology company. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development and DNA as a digital data storage medium. Twist Bioscience Corporation is headquartered in San Francisco, California.
Catherine Ramsey analyst at Robert W. Baird reiterates coverage on Twist Bioscience (TWST) stock in the energy sector with a Buy rating and has set TWST's stock price target at $ 56.
TipRanks.com reports that Twist Bioscience currently has 4 analysts offering 12-month price targets on TWST and the consensus is a Strong Buy rating with an average stock price target of $53.67. The most recent TWST stock price we have is $56.56 and we are not making any TWST forecasts at this time.
In addition, TradingView issued a n/a rating for TWST over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on TWST. industrialstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on TWST, please click here >>
The editors at industrialstockmovers.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
IndustrialStockMovers.com keeps investors informed of the top moving stocks within the industrial sector. We provide investors with timely information regarding top moving stocks in the industrial sector sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to IndustrialStockMovers.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================